Related Experiment Video
Updated: Dec 3, 2025
07:32
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.7K
Increased E2F2 predicts poor prognosis in patients with HCC based on TCGA data
Zhili Zeng1, Zebiao Cao1, Ying Tang2
1Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong, China.
BMC Cancer
|October 29, 2020
Summary
Increased E2F2 expression correlates with advanced hepatocellular carcinoma (HCC) stages and poorer survival. This suggests E2F2 as a potential prognostic biomarker and therapeutic target for HCC patients.
Area of Science:
- Molecular Oncology
- Cancer Genomics
- Hepatocellular Carcinoma Research
Background:
- The transcription factor E2F2 is implicated in various cancers, but its role in hepatocellular carcinoma (HCC) is not well-defined.
- Understanding E2F2's association with HCC is crucial for identifying new diagnostic and therapeutic strategies.
Purpose of the Study:
- To investigate the expression, clinical significance, and prognostic value of E2F2 in hepatocellular carcinoma (HCC).
- To explore the potential biological pathways influenced by E2F2 in HCC development and progression.
Main Methods:
- Analysis of HCC patient data from The Cancer Genome Atlas (TCGA).
- Statistical analyses including Wilcoxon, Kruskal-Wallis, logistic regression, Cox regression, and Kaplan-Meier.
- Gene Set Enrichment Analysis (GSEA) to identify enriched biological pathways.
Main Results:
- E2F2 expression was significantly elevated in HCC tissues and correlated with advanced histologic grade, clinical stage, T stage, tumor status, and alpha-fetoprotein levels.
- High E2F2 expression was associated with unfavorable overall survival (OS), progression-free interval (PFI), disease-free interval (DFI), and disease-specific survival (DSS).
- E2F2 independently predicted poor OS, DFI, and PFI in HCC patients.
- GSEA revealed enrichment of cell cycle, DNA replication, p53 signaling, and metabolic pathways in tumors with high E2F2 expression.
Conclusions:
- Elevated E2F2 serves as a potential independent prognostic biomarker for HCC.
- E2F2 represents a promising therapeutic target for hepatocellular carcinoma.
- Cell cycle, pyrimidine metabolism, DNA replication, p53 signaling, and ubiquitin-mediated proteolysis pathways are likely involved in E2F2's role in HCC.
